Immucell Corp

ICCCNASDAQUSD
9.87 USD
0.18 (1.79%)AT CLOSE (11:59 AM EDT)
9.89
0.02 (0.21%)
POST MARKET (AS OF 04:15 PM EDT)
Post Market
AS OF 04:15 PM EDT
9.89
0.02 (0.21%)
🔴Market: CLOSED
Open?$10.13
High?$10.13
Low?$9.82
Prev. Close?$10.05
Volume?8.7K
Avg. Volume?29.9K
VWAP?$9.90
Rel. Volume?0.29x
Bid / Ask
Bid?$8.17 × 100
Ask?$11.52 × 100
Spread?$3.35
Midpoint?$9.84
Valuation & Ratios
Market Cap?90.9M
Shares Out?9.0M
Float?6.5M
Float %?71.9%
P/E Ratio?N/A
P/B Ratio?3.12
EPS?-$0.06
Dividend?0.00%
Ex-Dividend?N/A

Immucell Corp (ICCC) trades at $9.86 per share. Our models show a "Buy" technical signal alongside a "Neutral" fundamental rating. This is driven by a robust Altman Z-Score, a strong Piotroski F-Score of 7/9, negative Return on Equity, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, ICCC trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Jun 4, 2026.

News
Profile
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Employees
73
Market Cap
90.9M
Industry
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Listed
1987-07-08
Address
56 EVERGREEN DR
PORTLAND, ME 04103
Phone: (207) 878-2770
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+2/3)
Medium-Term (Wave)? Neutral(0/3)
Short-Term (Ripple)? Bearish(-2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
88
Z-Score?
96
Momentum?
8
Short Sent.?
80
Piotroski F-Score?7/9Strong
Altman Z-Score?4.49Safe
Confidence?46%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?0.16%Low
Short Interest?10.4K
Days to Cover?1.0
Free Float6.5M
Avg Daily Volume27.3K
Settlement Date2026-05-15
Financial Health
Current Ratio?4.82Strong
Quick Ratio?2.60Strong
Cash Ratio?1.74Strong
Debt/Equity?0.30Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A
P/B?
Peers
100
S&P
54
3.12FAIR
P/S?
Peers
100
S&P
50
3.04FAIR
P/FCF?
Peers
100
S&P
35
26.9FAIR
EV/EBITDA?
Peers
100
S&P
33
18.3FAIR
EV/Sales?
Peers
100
S&P
59
3.10FAIR
Returns & Efficiency
ROE?
S&P
14
-1.9%WEAK
ROA?
S&P
3
-1.2%WEAK
Cash Flow & Enterprise
FCF?$3.4M
Enterprise Value?$92.8M
Fundamentals ratios updated end of day